According to Internet analytics provider comScore, patients who visit a drug brand's website are more likely to end up taking that drug than those who don't. FDA is aware of this and cited a Prevention Magazine
2011 survey that found that 49 percent of respondents who went online for prescription drug information reported seeking this information on a specific brand's Web site.
As a consequence of this influence of the Internet, FDA is currently studying how consumers interact with drug.com websites. Specifically, according to an April, 2011, public notice, FDA has a number of questions surrounding how to achieve "fair balance" in online DTC promotion.
This article reviews the study "Examination of Online Direct-to-Consumer Prescription Drug Promotion" (FDA-2011-N-0230), which is designed to test different ways of presenting prescription drug risk and benefit information on branded drug Web sites.
Topics include (partial list)
The full version of this article is available to subscribers. Subscription is free.
- Is FDA Out of Touch?
- Format & Visibility of ISI
- Table: Recent Rx Drug Advertising Studies proposed by FDA
- What About Online Testimonials?
- To Link or Not To Link?
- Impact on Internet Guidance